Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Biovica International AB (publ)    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Biovica International : announces initial results in clinical genomics study of DiviTum«TKa

11/18/2020 | 02:00am EST

November 18, 2020 -- Biovica, active in cancer diagnostics, today announced that initial results from the PROMISE study (NCT03281902) will be presented at the San Antonio Breast Cancer Symposium (December 8-11, 2020).

The PROMISE Study is evaluating the use of genomics in correlation with TK activity (TKa) to improve monitoring of breast cancer treatment.

“We are developing increased knowledge regarding the use of genomics and TKa measurements as tools for potential early identification of tumor response and resistance when treating patients with hormone receptor positive, HER2-negative metastatic breast cancer,” said Ciara O´Sullivan, M.B, B.Ch. BAO, an oncologist at Mayo Clinic and principal investigator of the study.

For the study, researchers used DiviTum®TKa to analyze serum samples from patients with metastatic breast cancer collected pre-treatment and after two cycles of standard combination treatment of endocrine therapy and a CDK 4/6 inhibitor. The aim of the study is to analyze the predictive capacity of DiviTum®TKa to evaluate efficacy and provide a comprehensive genomic assessment in order to identify novel genomic variants and pathways associated with an early decline in TKa.

Sixty-three patients were enrolled on PROMISE, which closed to new patient accrual in July 2020. In this initial analysis of 32 patients, there was a difference in genomic expression depending on whether patients had high or low TKa levels. The pattern between TKa and individual patients’ genomic expression profiles may be important for future monitoring of metastatic breast cancer, with the goal of testing new therapeutic approaches to overcome resistance to CDK4/6 inhibitors and endocrine therapy. The study is ongoing and will report updated data from additional time points and greater numbers of patients in the future.

“We are excited to once again collaborate with the Mayo Clinic in this important study to increase knowledge about resistance mechanisms and using DiviTum®TKa together with other biomarkers in the monitoring of metastatic breast cancer,” said Anders Rylander, CEO of Biovica.

© Modular Finance, source Nordic Press Releases

All news about BIOVICA INTERNATIONAL AB (PUBL)
01/18BIOVICA INTERNATIONAL : DiviTum«TKa in early treatment resistance trial
AQ
01/16BIOVICA INTERNATIONAL : FDA resource reallocation continues to impact DiviTum«TK..
AQ
01/12BIOVICA INTERNATIONAL : CEO and main shareholder lends shares for redemption of ..
AQ
2020BIOVICA INTERNATIONAL : Q2 Interim Report August-October 2020/2021
AQ
2020BIOVICA INTERNATIONAL : DiviTum«TKa included in new UK breast cancer study
AQ
2020BIOVICA INTERNATIONAL : Multicenter study PYTHIA presents positive DiviTum«TKa r..
AQ
2020BIOVICA INTERNATIONAL : CDK 4/6 dosing study supports DiviTum«TKa as an early an..
AQ
2020BIOVICA INTERNATIONAL : announces initial results in clinical genomics study of ..
AQ
2020BIOVICA INTERNATIONAL : DiviTum«TKa Monitoring Capabilities Confirmed in SWOG St..
AQ
2020BIOVICA INTERNATIONAL : FDA submission will proceed to substantive review
AQ
More news
Financials
Sales 2021 3,00 M 0,36 M 0,36 M
Net income 2021 -38,5 M -4,61 M -4,61 M
Net cash 2021 134 M 16,0 M 16,0 M
P/E ratio 2021 -32,2x
Yield 2021 -
Capitalization 1 269 M 152 M 152 M
EV / Sales 2021 379x
EV / Sales 2022 26,6x
Nbr of Employees 21
Free-Float 75,2%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Technical analysis trends BIOVICA INTERNATIONAL AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 3
Average target price 67,00 SEK
Last Close Price 44,90 SEK
Spread / Highest target 129%
Spread / Average Target 49,2%
Spread / Lowest Target -31,0%
EPS Revisions
Managers and Directors
NameTitle
Anders Rylander Chief Executive Officer & Director
Lars Erik Holmqvist Chairman
Adam Germunder Operations Director
Cecilia Driving CFO, Head-Human Resource, IR & EVP
Mattias Bergqvist Director-Clinical Development
Sector and Competitors